<DOC>
	<DOCNO>NCT02103673</DOCNO>
	<brief_summary>The population dementia increase rapidly . Cognitive impairment well Behavioral psychological symptom dementia ( BPSD ) add heavy burden caregiver . NMDA activation critical learning memory . Individuals Alzheimer 's disease ( AD ) few NMDA receptor frontal cortex hippocampus control . This study randomize , double-blind , placebo-controlled drug trial . All patient allocate randomly two group : ( 1 ) NMDA enhancer : DAOIB ( start dosage : 250-500 mg/day ) , ( 2 ) placebo , 6 week . The investigator hypothesize DAOIB may yield good efficacy placebo cognitive function clinical symptom patient BPSD .</brief_summary>
	<brief_title>DAOIB Treatment Cognitive Function Behavioral Psychological Symptoms Dementia</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<criteria>Clinical diagnosis probable Alzheimer 's disease probable vascular dementia For patient vascular dementia , poststroke period must 3 month MiniMental State score 526 Clinical Dementia Rating score equal great 1 Behavioral Pathology Alzheimer 's Disease Rating Scale score equal great 2 Current substance abuse history substance dependence past 6 month Other major psychiatric diagnosis , schizophrenia , major depressive disorder , bipolar disorder mental retardation etc . Serious medical neurological illness Alzheimer 's disease/vascular dementia secondary dementia</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>